| abstract |
This disclosure characterizes chemical entities (e.g., a compound that exhibits activity as a mitochondrial decoupling agent or a pharmaceutically acceptable salt and / or hydrate and / or co-crystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and / or hydrate and / or co-crystal thereof; e.g., a compound, such as a niclosamide analogue, or a pharmaceutically acceptable salt and / or hydrate and / or co-crystal thereof) which are useful, eg, for the treatment of one or more symptoms of a pathology characterized by an abnormal inflammatory response (eg, inflammatory bowel disorder) in an individual (eg, a human ). Also, this disclosure characterizes compositions, in addition to other methods for using and making them. |